Business
Tetra and Prepaire Jointly Apply to BARDA for Funding
Tetra and Prepaire Jointly Apply to BARDA for Funding.
About this update from Tetra Bio-pharma Inc.
[{"type":"text","content":"\n\n\n\nTetra and Prepaire Jointly Apply to BARDA for Funding\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nTetra and Prepaire Jointly Apply to BARDA for Funding\nPR Newswire\nOTTAWA, ON, Oct. 11, 2022\n\n\n\nCompanies jointly submitted a $750,000 USD application to BARDA to use Prepaire™ Shield discovery platform to assess repurposed drugs combined with onternabez as Chemical Threat Medical Countermeasures.Partnership leverages respective expertise, technology, and capabilities to identify new combination therapies and improve clinical trajectories of patients exposed to pulmonary and nerve chemical agents. OTTAWA, ON, Oct. 11, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc. (\"Tetra\" or the \"Company\") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today it has successfully submitted, in collaboration with Prepaire, a grant application to the Office of Biomedical Advanced Research and Development Authority (BARDA), Division of Research, Innovation and Ventures (DRIVe).\n\n \n \n \n \n \n \n\n \nThe project aims at improving the management of patients exposed to pulmonary (i.e., chlorine, phosphogene) or nerve chemical agents (i.e., Sarin, Soman, or Tabun) and optimize their clinical trajectories to minimize the outcome following mass casualty events.\nTetra and Prepaire will combine their respective expertise and capabilities to reinvent the drug development process through a fast, innovative, and cost-effective approach using the Prepaire™ Shield discovery platform and Tetra's proprietary compound, onternabez. Prepaire™ Shield is an integrated multi-modal/level data solution encompassing state-of-the-art Artificial Intelligence (AI) to generate new potential combination treatments with in vitro validation testing using induced pluripotent stem cells (IPSC) and a retrosynthesis tool to help develop a comprehensive Clinical Decision Support system. Newly identified therapies will include repurposed drugs combined with Tetra's investigational compound, onternabez, to treat acute and lon...